Comparison of the ocular surface changes following the use of two different prostaglandin F2α analogues containing benzalkonium chloride or polyquad in rabbit eyes

References

• Strutton DR, Walt JG. Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. J Glaucoma 2004;13:221–226
   PubMed Web of Science ®Google Scholar
• van der Valk R, Schouten JS, Webers CA, et al. The impact of a nationwide introduction of new drugs and a treatment protocol for glaucoma on the number of glaucoma surgeries. J Glaucoma 2005;14:239–242
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea 2010;29:618–621
   PubMed Web of Science ®Google Scholar
• Schein OD, Munoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol 1997;124:723–728
   PubMed Web of Science ®Google Scholar
• Nordmann JP, Auzanneau N, Ricard S, Berdeaux G. Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes 2003;1:75
   PubMedGoogle Scholar
• Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol 2012;153:1–9 e2
   PubMed Web of Science ®Google Scholar
• Anwar Z, Wellik SR, Galor A. Glaucoma therapy and ocular surface disease: current literature and recommendations. Curr Opin Ophthalmol 2013;24:136–143
   PubMed Web of Science ®Google Scholar
• Blondin C, Hamard P, Cholley B, et al. In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system. Curr Eye Res 2003;27:253–259
   PubMed Web of Science ®Google Scholar
• Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther 2010;27:837–845
   PubMed Web of Science ®Google Scholar
• Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther 2006;23:663–671
   PubMed Web of Science ®Google Scholar
• Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells. Adv Ther 2011;28:501–510
   PubMed Web of Science ®Google Scholar
• Malvitte L, Montange T, Vejux A, et al. Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs. Br J Ophthalmol 2007;91:29–32
   PubMed Web of Science ®Google Scholar
• Baudouin C, Hamard P, Liang H, et al. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 2004;111:2186–2192
   PubMed Web of Science ®Google Scholar
• Thakur A, Willcox MD. Cytokine and lipid inflammatory mediator profile of human tears during contact lens associated inflammatory diseases. Exp Eye Res 1998;67:9–19
   PubMed Web of Science ®Google Scholar
• Torres P, de Vos AF, van der Gaag R, Kijlstra A. Expression of the interleukin 1 receptor antagonist in the normal human cornea. Ocul Immunol Inflamm 1994;2:217–222
   PubMedGoogle Scholar
• Ayaki M, Iwasawa A. Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines. Clin Ophthalmol 2010;4:919–924
   PubMedGoogle Scholar
• Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea 2008;27:339–343
   PubMed Web of Science ®Google Scholar
• Kim JR, Oh TH, Kim HS. Effects of benzalkonium chloride on the ocular surface of the rabbit. Jpn J Ophthalmol 2011;55:283–293
   PubMed Web of Science ®Google Scholar
• Liang H, Baudouin C, Pauly A, Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol 2008;92:1275–1282
   PubMed Web of Science ®Google Scholar
• Liang H, Brignole-Baudouin F, Pauly A, et al. Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. Adv Ther 2011;28:311–325
   PubMed Web of Science ®Google Scholar
• Liang H, Pauly A, Riancho L, et al. Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. Br J Ophthalmol 2011;95:869–875
   PubMed Web of Science ®Google Scholar
• Guenoun JM, Baudouin C, Rat P, et al. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005;46:4594–4599
   PubMed Web of Science ®Google Scholar